| Multiple drug resistance and biocide resistance in Escherichia coli environmental isolates from hospital and household settings B Ghanem, RN Haddadin Antimicrobial Resistance & Infection Control 7, 1-7, 2018 | 41 | 2018 |
| Analysis of the gene therapies authorized by the United States Food and Drug Administration and the European Medicines Agency B Ghanem, E Seoane-Vazquez, L Brown, R Rodriguez-Monguio Medical Care 61 (7), 438-447, 2023 | 7 | 2023 |
| The economic burden of CAR T cell therapies ciltacabtagene autoleucel and idecabtagene vicleucel for the treatment of adult patients with relapsed or refractory multiple … B Ghanem, L Shi BioDrugs 36 (6), 773-780, 2022 | 6 | 2022 |
| Efficacy, safety, and cost-minimization analysis of axicabtagene ciloleucel and tisagenlecleucel CAR T-Cell therapies for treatment of relapsed or refractory follicular lymphoma B Ghanem Investigational New Drugs 41 (5), 710-718, 2023 | 2 | 2023 |
| The Association of Medicaid expansion with prescription drug utilization and expenditure among low-income participants with asthma L Shi, T Li, J Luck, B Ghanem Journal of Asthma 60 (11), 2030-2039, 2023 | 1 | 2023 |
| Safety of Adalimumab: An Analysis of the FDA Adverse Event Reporting System (FAERS) Database B Ghanem Jordan Journal of Pharmaceutical Sciences 16 (3), 517-528, 2023 | | 2023 |
| EPH94 Gender, Ethnic, and Racial Disparities Among Cell and Gene Therapy Clinical Trials B Ghanem, M Fleming, LM Brown, R Rodriguez-Monguio, ... Value in Health 26 (6), S181, 2023 | | 2023 |
| HPR148 A Disproportionality Analysis of the Serious Adverse Drug Events Associated with Gene Therapy Products Using the FDA Adverse Event Reporting System (FAERS) B Ghanem, M Fleming, LM Brown, R Rodriguez-Monguio, ... Value in Health 26 (6), S237, 2023 | | 2023 |
| EE86 Cost-Effectiveness Analysis of Axicabtagene Ciloleucel, Lisocabtagene Maraleucel, and Tisagenlecleucel CAR T-Cell Therapies for Treatment of Relapsed or Refractory Large B … B Ghanem, E Seoane-Vazquez, M Fleming, LM Brown, ... Value in Health 26 (6), S75, 2023 | | 2023 |
| An Economic and Regulatory Analysis of Gene Therapy Products Authorized by the US Food and Drug Administration and the European Medicines Agency B Ghanem | | 2023 |
| Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Multiple Myeloma Patients B Ghanem, ML Fleming, LM Brown, R Rodriguez-Monguio, ... | | 2023 |
| Budget Impact Analysis of Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US B Ghanem, L Shi Clinical Drug Investigation 42 (12), 1085-1092, 2022 | | 2022 |
| EE213 Cost-Effectiveness Analysis of Axicabtagene Ciloleucel, Brexucabtagene Autoleucel, and Standard of Care for Treatment of Relapsed/Refractory Mantle Cell Lymphoma B Ghanem, L Brown, E Seoane-Vazquez Value in Health 25 (7), S375, 2022 | | 2022 |
| PDG38 ASSESSMENT OF GENERIC COMPETITION FOR ORPHAN DRUGS MARKETED IN THE US (1993-2019) B Ghanem, H Althobaiti, G Phillipe, R Rodriguez-Monguio, ... Value in Health 23, S136, 2020 | | 2020 |
